BeOne Medicines Ltd. — Director's Dealing 2022

Mar 2, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2022-02-28

Reporting Person: Wang Julia Aijun (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-02-28	Ordinary Shares	A	61750	—	Acquired	143299	Direct

Footnotes

F1: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of February 28, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

F2: Includes 1,677 ordinary shares acquired pursuant to the Company's Second Amended and Restated 2018 Employee Share Purchase Plan.